Implementation of an FDA-cleared tumor profiling assay to enable localized Precision Oncology testing for patients

At a large cancer center that provides care to many rural, medically underserved communities, oncologists see a high overall cancer mortality burden. To help improve healthcare outcomes for these communities, the cancer center began implementing PGDx elio^TM tissue complete, an FDA-cleared, assay-to-report in vitro diagnostic (IVD) solution for solid tumor profiling. In a webinar co-hosted by CAP TODAY, a panel of speakers from the cancer center discuss the benefits of rapid biomarker identification with this comprehensive approach, the potential to provide a clearer path to reimbursement and the research opportunities that are possible with PGDx elio tissue complete.

Speakers Info

Alexander Craig Mackinnon, Jr, MD, PhD

Professor, Department of Pathology, University of Alabama at Birmingham

Shuko Harada, MD

Professor, Department of Pathology — Genomic Diagnostics and Bioinformatics, University of Alabama at Birmingham

Darshan Chandrashekar, PhD

Assistant Professor, Department of Pathology — Genomic Diagnostics and Bioinformatics, University of Alabama at Birmingham

Webinar

Implementation of an FDA-cleared tumor profiling assay to enable localized Precision Oncology testing for patients

Educational tools to facilitate local comprehensive genomic profiling implementation